German pharma and lab supplier Sartorius reported that fiscal 2023 profit to equity holders of Sartorius AG declined to €205.2 million ($220 million) from €678.1 million, last year. Earnings per share reached €2.99 compared to €9.91. Relevant net profit to shareholders of Sartorius fell by 48.3% to €338.5 million euros. Underlying earnings per ordinary share decreased by 48.4% to €4.94 from €9.57. Fiscal year group sales revenue decreased by 16.6% in constant currencies to €3.40 billion in 2023.